Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 3, 2025 • 5:01 PM ET

Date/Time Source News Release
12/19/2024 09:00 AM EST ACCESSWIRE MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
12/10/2024 08:30 AM EST ACCESSWIRE MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
11/20/2024 07:44 AM EST ACCESSWIRE MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
10/28/2024 07:30 AM EDT ACCESSWIRE MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
10/21/2024 07:30 AM EDT ACCESSWIRE MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
09/27/2024 07:30 AM EDT ACCESSWIRE MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
09/11/2024 07:30 AM EDT ACCESSWIRE MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
08/26/2024 08:00 AM EDT ACCESSWIRE MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
08/19/2024 07:30 AM EDT ACCESSWIRE MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
08/12/2024 08:00 AM EDT ACCESSWIRE MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
Page